INSULET CORP
Close on Oct 19, 2026
- Market cap
- $9.85B
- P/E (TTM)
- 26.5
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $801.70M | $1.37 | $1.66 |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $761.70M | $1.30 | $1.42 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 18, 2026 | Before market open | $783.80M | $1.44 | $1.55 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $706.30M | $1.24 | $1.24 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $649.10M | $0.32 | $1.17 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $569.00M | $0.50 | $1.02 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 20, 2025 | After market close | $597.50M | $1.39 | $1.15 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $543.90M | $1.08 | $0.90 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EPS Growthnon-GAAP | FY 2026 Guidance (as of 8/5/2026) | 30% growth | Raised |
| Adjusted Operating Marginnon-GAAP | FY 2026 Guidance (as of 8/5/2026) | 100 | New |
| Adjusted Operating Marginnon-GAAP | Q3 2026 | 100 | New |
| International Omnipodnon-GAAP | Q3 2026 | 28% to 30% growth | Raised |
| U.S. Omnipodnon-GAAP | Q3 2026 | 14% to 16% growth | New |
| TotalGAAP | Three Months Ended September 30, 2026 | 17% to 19% growth | Raised |
| Drug DeliveryGAAP | Three Months Ended September 30, 2026 | -20% growth | Lowered |
| Total OmnipodGAAP | Three Months Ended September 30, 2026 | 17.5% to 19.5% growth | Lowered |
| International OmnipodGAAP | Three Months Ended September 30, 2026 | 26% to 28% growth | Raised |
| U.S. OmnipodGAAP | Three Months Ended September 30, 2026 | 14% to 16% growth | New |
| Totalnon-GAAP | Q3 2026 | 17.5% to 19.5% growth | Raised |
| Total Omnipodnon-GAAP | FY 2026 Guidance (as of 8/5/2026) | 21% to 23% growth | Lowered |
| International Omnipodnon-GAAP | FY 2026 Guidance (as of 8/5/2026) | 30% to 32% growth | Raised |
| U.S. Omnipodnon-GAAP | FY 2026 Guidance (as of 8/5/2026) | 17% to 19% growth | Lowered |
| TotalGAAP | Year Ending December 31, 2026 | 21% to 23% growth | Raised |
| Drug DeliveryGAAP | Year Ending December 31, 2026 | -40% growth | Lowered |
| Total OmnipodGAAP | Year Ending December 31, 2026 | 22% to 24% growth | Lowered |
| International OmnipodGAAP | Year Ending December 31, 2026 | 33% to 35% growth | Raised |
| U.S. OmnipodGAAP | Year Ending December 31, 2026 | 17% to 19% growth | Lowered |
| Totalnon-GAAP | FY 2026 Guidance (as of 8/5/2026) | 20% to 22% growth | Lowered |
| Drug Deliverynon-GAAP | Q3 2026 | -20% growth | Lowered |
| Total Omnipodnon-GAAP | Q3 2026 | 18% to 20% growth | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Insulet filed with the SEC
Insulet Reports Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Reports First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.
Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Reports Fourth Quarter and Full Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Reports Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Insulet Announces Appointment of Robert L. Huffines to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Flavia Pease Appointed Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9%
Results of operations · EX-99.1 to Form 8-K
Insulet Reports First Quarter 2025 Revenue Increase of 29%
Results of operations · EX-99.1 to Form 8-K
Insulet Appoints Ashley McEvoy President and CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Announces Pricing of Senior Notes Due 2033
Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Announces Proposed Financing Transactions
Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Reports Full Year 2024 Revenue Increase of 22%
Results of operations · EX-99.1 to Form 8-K
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
Other events · EX-99.1 to Form 8-K
Insulet Reports Third Quarter 2024 Revenue Increase of 26%
Results of operations · EX-99.1 to Form 8-K
Insulet Reports Second Quarter 2024 Revenue Increase of 23%
Results of operations · EX-99.1 to Form 8-K
Insulet Reports Preliminary Second Quarter 2024 Revenue Results
Results of operations · EX-99.1 to Form 8-K
Insulet Reports First Quarter 2024 Revenue Increase of 23%
Results of operations · EX-99.1 to Form 8-K
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% constant currency 1 )
Results of operations · EX-99.1 to Form 8-K
Insulet Announces Changes to Board of Directors with Retirements and New Appointments
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Reports Third Quarter 2023 Revenue Increase of 27%
Results of operations · EX-99.1 to Form 8-K
Reaffirms Guidance for Third Quarter and Fiscal Year 2023
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Reports Second Quarter 2023 Revenue Increase of 32%
Results of operations · EX-99.1 to Form 8-K
EOFLOW CO., LTD.; EOFLOW, INC.; :
Other events · EX-99.1 to Form 8-K
Insulet Announces New Organizational Structure to Drive Further Growth
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Insulet Reports First Quarter 2023 Revenue Increase of 21%
Results of operations · EX-99.1 to Form 8-K
Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency 1 )
Results of operations · EX-99.1 to Form 8-K/A
Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency 1 )
Results of operations · EX-99.1 to Form 8-K